z-logo
Premium
Target tissue ectoenzyme CD 39/ CD 73‐expressing Foxp3 + regulatory T cells in patients with psoriasis
Author(s) -
Zhang H. Y.,
Yan K. X.,
Huang Q.,
Ma Y.,
Fang X.,
Han L.
Publication year - 2015
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12497
Subject(s) - psoriasis , foxp3 , dermis , medicine , epidermis (zoology) , biopsy , immunohistochemistry , staining , population , pathology , immunology , dermatology , immune system , anatomy , environmental health
Summary Background Psoriasis is a chronic, relapsing, inflammatory skin disease, in which regulatory T cells (Tregs) play an important role. Recently, human Treg ectoenzymes ( CD 39/ CD 73) have been reported to mediate the suppressive activity of Tregs. Aim To investigate the proportions of CD 39/ CD 73 expressing Foxp3 + regulatory T cells in different types of psoriatic lesions. Methods Immunohistochemical staining was used to analyse expression of Foxp3, CD 39 and CD 73 in biopsy tissue from healthy controls and from patients with different types of psoriasis. Results In normal control biopsies, CD 39 + cells were scattered throughout the epidermis and dermis, while CD 73 + cells were localized predominantly in the dermis. The proportion of cells that were both CD 39 + and Foxp3 + was significantly lower in pustular psoriasis ( PP ) and erythrodermic psoriasis ( EP ) than in psoriasis vulgaris ( PV ) (25.0 ± 2.6%, 26.5 ± 2.0% and 45.1 ± 3.5%, respectively; P  < 0.001). Likewise, CD 73 + Foxp3 + cells were lower in PP and EP than in PV (6.2 ± 1.9%, 11.6 ± 2.8% and 17.7 ± 2.3% respectively, P  < 0.001). There were no significant differences in the population size of double‐staining cells in EP compared with PP . Conclusion The relative reduced expressions of CD 39 and CD 73 within Foxp3 + Tregs may imply a different immunopathogenesis for different psoriatic lesions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here